Concepedia

Publication | Open Access

Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma

DOIFull Paper Access

288

Citations

16

References

2007

Year

Burt Nabors, Tom Mikkelsen, Steven S. Rosenfeld, Fred H. Hochberg, Narasimha S. Akella, Joy Fisher, Gretchen A. Cloud, Yu Zhang, K. Carson, Sabine M. Wittemer,
Journal of Clinical Oncology

Abstract

Cilengitide is well tolerated to doses of 2,400 mg/m2, durable complete and partial responses were seen in this phase I study, and clinical response appears related to rCBF changes.

References

YearCitations

Page 1